• Je něco špatně v tomto záznamu ?

Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial

MG. Della Porta, G. Garcia-Manero, V. Santini, AM. Zeidan, RS. Komrokji, J. Shortt, D. Valcárcel, A. Jonasova, S. Dimicoli-Salazar, IS. Tiong, CC. Lin, J. Li, J. Zhang, R. Pilot, S. Kreitz, V. Pozharskaya, KL. Keeperman, S. Rose, T. Prebet, Y....

. 2024 ; 11 (9) : e646-e658. [pub] 20240719

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, klinické zkoušky, fáze III, randomizované kontrolované studie, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc24019089

BACKGROUND: The preplanned interim analysis of the COMMANDS trial showed greater efficacy of luspatercept than epoetin alfa for treating anaemia in erythropoiesis-stimulating agent (ESA)-naive patients with transfusion-dependent, lower-risk myelodysplastic syndromes. In this Article, we report the results of the primary analysis of the trial. METHODS: COMMANDS is a phase 3, open-label, randomised, controlled trial conducted at 142 sites in 26 countries. Eligible patients were those aged 18 years or older, with myelodysplastic syndromes of very low risk, low risk, or intermediate risk (as defined by the Revised International Prognostic Scoring System), who were ESA-naive and transfusion dependent, and had a serum erythropoietin concentration of less than 500 U/L. Patients were stratified by baseline red blood cell transfusion burden, serum erythropoietin concentration, and ring sideroblast status, and randomly allocated (1:1) to receive luspatercept (1·0-1·75 mg/kg body weight, subcutaneously, once every 3 weeks) or epoetin alfa (450-1050 IU/kg body weight, subcutaneously, once a week; maximum total dose 80 000 IU) for at least 24 weeks. The primary endpoint was red blood cell transfusion independence lasting at least 12 weeks with a concurrent mean haemoglobin increase of at least 1·5 g/dL (weeks 1-24), evaluated in the intention-to-treat population. The safety population included all patients who received at least one dose of treatment. This trial is registered with ClinicalTrials.gov (NCT03682536; active, not recruiting). FINDINGS: Between Jan 2, 2019, and Sept 29, 2022, 363 patients were screened and randomly allocated: 182 (50%) to luspatercept and 181 (50%) to epoetin alfa. Median age was 74 years (IQR 69-80), 162 (45%) patients were female, and 201 (55%) were male. 289 (80%) were White, 44 (12%) were Asian, and two (1%) were Black or African American. 23 (6%) were Hispanic or Latino and 311 (86%) were not Hispanic or Latino. Median follow-up for the primary endpoint was 17·2 months (10·4-27·7) for the luspatercept group and 16·9 months (10·1-26·6) for the epoetin alfa group. A significantly greater proportion of patients in the luspatercept group reached the primary endpoint (110 [60%] vs 63 [35%]; common risk difference on response rate 25·4% [95% CI 15·8-35·0]; p<0·0001). Median follow-up for safety analyses was 21·4 months (IQR 14·2-32·4) for the luspatercept group and 20·3 months (12·7-30·9) for the epoetin alfa group. Common grade 3-4 treatment-emergent adverse events occurring among luspatercept recipients (n=182) were hypertension (19 [10%] patients), anaemia (18 [10%]), pneumonia (ten [5%]), syncope (ten [5%]), neutropenia (nine [5%]), thrombocytopenia (eight [4%]), dyspnoea (eight [4%]), and myelodysplastic syndromes (six [3%]); and among epoetin alfa recipients (n=179) were anaemia (14 [8%]), pneumonia (14 [8%]), neutropenia (11 [6%]), myelodysplastic syndromes (ten [6%]), hypertension (eight [4%]), iron overload (seven [4%]), and COVID-19 pneumonia (six [3%]). The most common serious treatment-emergent adverse events in both groups were pneumonia (nine [5%] luspatercept recipients and 13 [7%] epoetin alfa recipients) and COVID-19 (eight [4%] luspatercept recipients and ten [6%] epoetin alfa recipients). One death (due to acute myeloid leukaemia) considered to be luspatercept-related was reported at the interim analysis. INTERPRETATION: Luspatercept represents a new standard of care for ESA-naive patients with transfusion-dependent, lower-risk myelodysplastic syndromes. Significantly more patients had red blood cell transfusion independence and haematological improvement with luspatercept than with epoetin alfa, with benefits observed across patient subgroups. FUNDING: Celgene and Acceleron Pharma.

Bristol Myers Squibb Princeton NJ USA

Cancer Center IRCCS Humanitas Research Hospital Milan Italy

Celgene International Sàrl a Bristol Myers Squibb Company Boudry Switzerland

Département d'Hématologie Clinique Université Cote d'Azur CHU Nice Nice France

Department of Biomedical Sciences Humanitas University Milan Italy

Department of Internal Medicine Yale School of Medicine and Yale Cancer Center Yale University New Haven CT USA

Department of Laboratory Medicine National Taiwan University Hospital Taipei Taiwan

Department of Leukemia University of Texas M D Anderson Cancer Center Houston TX USA

Department of Pathology Peter MacCallum Cancer Centre Melbourne VIC Australia

Hematology Oncology and Transfusion Medicine Center Vilnius University Hospital Santaros Klinikos Vilnius Lithuania

Hôpital Haut Lévêque Centre Hospitalier Universitaire de Bordeaux Bordeaux France

Institute of Clinical Medicine Faculty of Medicine Vilnius University Vilnius Lithuania

IRCCS Azienda Ospedaliero Universitaria di Bologna Istituto di Ematologia Seràgnoli Bologna Italy

Malignant Haematology and Stem Cell Transplantation The Alfred Melbourne VIC Australia

MDS Unit Hematology University of Florence DMSC AOUC Florence Italy

Medical Clinic and Policlinic 1 Hematology and Cellular Therapy University Hospital Leipzig Leipzig Germany

Medical Department Hematology Charles University General Hospital Prague Czech Republic

Moffitt Cancer Center Tampa FL USA

Monash University and Monash Health Melbourne VIC Australia

Service d'Hématologie Séniors Hôpital Saint Louis Université Paris 7 Paris France

Vall Hebron Institute of Oncology Hematology Department Vall d'Hebron University Hospital Universitat Autònoma de Barcelona Barcelona Spain

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24019089
003      
CZ-PrNML
005      
20241024111617.0
007      
ta
008      
241015s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/S2352-3026(24)00203-5 $2 doi
035    __
$a (PubMed)39038479
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Della Porta, Matteo Giovanni $u Cancer Center, IRCCS Humanitas Research Hospital, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Milan, Italy. Electronic address: matteo.della_porta@hunimed.edu
245    10
$a Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial / $c MG. Della Porta, G. Garcia-Manero, V. Santini, AM. Zeidan, RS. Komrokji, J. Shortt, D. Valcárcel, A. Jonasova, S. Dimicoli-Salazar, IS. Tiong, CC. Lin, J. Li, J. Zhang, R. Pilot, S. Kreitz, V. Pozharskaya, KL. Keeperman, S. Rose, T. Prebet, Y. Lai, A. Degulys, S. Paolini, T. Cluzeau, P. Fenaux, U. Platzbecker
520    9_
$a BACKGROUND: The preplanned interim analysis of the COMMANDS trial showed greater efficacy of luspatercept than epoetin alfa for treating anaemia in erythropoiesis-stimulating agent (ESA)-naive patients with transfusion-dependent, lower-risk myelodysplastic syndromes. In this Article, we report the results of the primary analysis of the trial. METHODS: COMMANDS is a phase 3, open-label, randomised, controlled trial conducted at 142 sites in 26 countries. Eligible patients were those aged 18 years or older, with myelodysplastic syndromes of very low risk, low risk, or intermediate risk (as defined by the Revised International Prognostic Scoring System), who were ESA-naive and transfusion dependent, and had a serum erythropoietin concentration of less than 500 U/L. Patients were stratified by baseline red blood cell transfusion burden, serum erythropoietin concentration, and ring sideroblast status, and randomly allocated (1:1) to receive luspatercept (1·0-1·75 mg/kg body weight, subcutaneously, once every 3 weeks) or epoetin alfa (450-1050 IU/kg body weight, subcutaneously, once a week; maximum total dose 80 000 IU) for at least 24 weeks. The primary endpoint was red blood cell transfusion independence lasting at least 12 weeks with a concurrent mean haemoglobin increase of at least 1·5 g/dL (weeks 1-24), evaluated in the intention-to-treat population. The safety population included all patients who received at least one dose of treatment. This trial is registered with ClinicalTrials.gov (NCT03682536; active, not recruiting). FINDINGS: Between Jan 2, 2019, and Sept 29, 2022, 363 patients were screened and randomly allocated: 182 (50%) to luspatercept and 181 (50%) to epoetin alfa. Median age was 74 years (IQR 69-80), 162 (45%) patients were female, and 201 (55%) were male. 289 (80%) were White, 44 (12%) were Asian, and two (1%) were Black or African American. 23 (6%) were Hispanic or Latino and 311 (86%) were not Hispanic or Latino. Median follow-up for the primary endpoint was 17·2 months (10·4-27·7) for the luspatercept group and 16·9 months (10·1-26·6) for the epoetin alfa group. A significantly greater proportion of patients in the luspatercept group reached the primary endpoint (110 [60%] vs 63 [35%]; common risk difference on response rate 25·4% [95% CI 15·8-35·0]; p<0·0001). Median follow-up for safety analyses was 21·4 months (IQR 14·2-32·4) for the luspatercept group and 20·3 months (12·7-30·9) for the epoetin alfa group. Common grade 3-4 treatment-emergent adverse events occurring among luspatercept recipients (n=182) were hypertension (19 [10%] patients), anaemia (18 [10%]), pneumonia (ten [5%]), syncope (ten [5%]), neutropenia (nine [5%]), thrombocytopenia (eight [4%]), dyspnoea (eight [4%]), and myelodysplastic syndromes (six [3%]); and among epoetin alfa recipients (n=179) were anaemia (14 [8%]), pneumonia (14 [8%]), neutropenia (11 [6%]), myelodysplastic syndromes (ten [6%]), hypertension (eight [4%]), iron overload (seven [4%]), and COVID-19 pneumonia (six [3%]). The most common serious treatment-emergent adverse events in both groups were pneumonia (nine [5%] luspatercept recipients and 13 [7%] epoetin alfa recipients) and COVID-19 (eight [4%] luspatercept recipients and ten [6%] epoetin alfa recipients). One death (due to acute myeloid leukaemia) considered to be luspatercept-related was reported at the interim analysis. INTERPRETATION: Luspatercept represents a new standard of care for ESA-naive patients with transfusion-dependent, lower-risk myelodysplastic syndromes. Significantly more patients had red blood cell transfusion independence and haematological improvement with luspatercept than with epoetin alfa, with benefits observed across patient subgroups. FUNDING: Celgene and Acceleron Pharma.
650    _2
$a lidé $7 D006801
650    12
$a epoetin alfa $x terapeutické užití $7 D000068817
650    12
$a myelodysplastické syndromy $x komplikace $x farmakoterapie $7 D009190
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a senioři $7 D000368
650    12
$a rekombinantní fúzní proteiny $x terapeutické užití $x škodlivé účinky $7 D011993
650    12
$a hematinika $x terapeutické užití $7 D006397
650    12
$a anemie $x farmakoterapie $x etiologie $7 D000740
650    _2
$a lidé středního věku $7 D008875
650    _2
$a imunoglobuliny - Fc fragmenty $x terapeutické užití $x škodlivé účinky $7 D007141
650    _2
$a erythropoetin $x terapeutické užití $7 D004921
650    _2
$a aktivinové receptory typu II $x terapeutické užití $7 D030301
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a výsledek terapie $7 D016896
650    _2
$a hemoglobiny $x analýza $7 D006454
650    _2
$a krevní transfuze $x statistika a číselné údaje $7 D001803
655    _2
$a časopisecké články $7 D016428
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Garcia-Manero, Guillermo $u Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
700    1_
$a Santini, Valeria $u MDS Unit, Hematology, University of Florence, DMSC, AOUC, Florence, Italy
700    1_
$a Zeidan, Amer M $u Department of Internal Medicine, Yale School of Medicine and Yale Cancer Center, Yale University, New Haven, CT, USA
700    1_
$a Komrokji, Rami S $u Moffitt Cancer Center, Tampa, FL, USA
700    1_
$a Shortt, Jake $u Monash University and Monash Health, Melbourne, VIC, Australia
700    1_
$a Valcárcel, David $u Vall Hebron Institute of Oncology (VHIO), Hematology Department, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain
700    1_
$a Jonasova, Anna $u Medical Department, Hematology, Charles University General Hospital, Prague, Czech Republic
700    1_
$a Dimicoli-Salazar, Sophie $u Hôpital Haut-Lévêque, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France
700    1_
$a Tiong, Ing Soo $u Malignant Haematology & Stem Cell Transplantation, The Alfred, Melbourne, VIC, Australia; Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
700    1_
$a Lin, Chien-Chin $u Department of Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan
700    1_
$a Li, Jiahui $u Bristol Myers Squibb, Princeton, NJ, USA
700    1_
$a Zhang, Jennie $u Bristol Myers Squibb, Princeton, NJ, USA
700    1_
$a Pilot, Richard $u Bristol Myers Squibb, Princeton, NJ, USA
700    1_
$a Kreitz, Sandra $u Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland
700    1_
$a Pozharskaya, Veronika $u Bristol Myers Squibb, Princeton, NJ, USA
700    1_
$a Keeperman, Karen L $u Bristol Myers Squibb, Princeton, NJ, USA
700    1_
$a Rose, Shelonitda $u Bristol Myers Squibb, Princeton, NJ, USA
700    1_
$a Prebet, Thomas $u Bristol Myers Squibb, Princeton, NJ, USA
700    1_
$a Lai, Yinzhi $u Bristol Myers Squibb, Princeton, NJ, USA
700    1_
$a Degulys, Andrius $u Hematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania; Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania
700    1_
$a Paolini, Stefania $u IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy
700    1_
$a Cluzeau, Thomas $u Département d'Hématologie Clinique, Université Cote d'Azur, CHU Nice, Nice, France
700    1_
$a Fenaux, Pierre $u Service d'Hématologie Séniors, Hôpital Saint-Louis, Université Paris 7, Paris, France
700    1_
$a Platzbecker, Uwe $u Medical Clinic and Policlinic 1, Hematology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany
773    0_
$w MED00193479 $t The Lancet. Haematology $x 2352-3026 $g Roč. 11, č. 9 (2024), s. e646-e658
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39038479 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241015 $b ABA008
991    __
$a 20241024111610 $b ABA008
999    __
$a ok $b bmc $g 2201734 $s 1231062
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 11 $c 9 $d e646-e658 $e 20240719 $i 2352-3026 $m The Lancet. Haematology $n Lancet Haematol $x MED00193479
LZP    __
$a Pubmed-20241015

Najít záznam

Citační ukazatele

Možnosti archivace